このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Evotec 将来の成長

Future 基準チェック /46

Evotec利益と収益がそれぞれ年間73.8%と11.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に4.3% 79.4%なると予測されています。

主要情報

73.4%

収益成長率

79.5%

EPS成長率

Life Sciences 収益成長	25.9%
収益成長率	11.4%
将来の株主資本利益率	3.6%
アナリストカバレッジ	Good
最終更新日	26 Sep 2024

今後の成長に関する最新情報

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 17

Recent updates

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 17

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 08

業績と収益の成長予測

XTRA:EVT - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,063	32	51	162	9
12/31/2025	949	-21	-4	99	11
12/31/2024	823	-148	-288	-49	10
6/30/2024	788	-171	-246	-55	N/A
3/31/2024	777	-91	-224	-12	N/A
12/31/2023	781	-84	-180	36	N/A
9/30/2023	821	-95	-191	-17	N/A
6/30/2023	798	-103	-246	-42	N/A
3/31/2023	800	-116	-39	143	N/A
12/31/2022	751	-176	24	206	N/A
9/30/2022	698	-180	121	297	N/A
6/30/2022	684	2	194	322	N/A
3/31/2022	650	90	58	183	N/A
12/31/2021	618	216	3	122	N/A
9/30/2021	571	247	-58	86	N/A
6/30/2021	541	112	-50	93	N/A
3/31/2021	515	42	-99	20	N/A
12/31/2020	501	6	-54	45	N/A
9/30/2020	485	14	-4	62	N/A
6/30/2020	470	35	0	46	N/A
3/31/2020	462	42	43	82	N/A
12/31/2019	446	38	10	42	N/A
9/30/2019	419	61	1	29	N/A
6/30/2019	404	77	46	74	N/A
3/31/2019	398	94	109	139	N/A
12/31/2018	375	84	128	156	N/A
9/30/2018	370	63	109	135	N/A
6/30/2018	338	31	54	80	N/A
3/31/2018	294	20	N/A	19	N/A
12/31/2017	264	23	N/A	11	N/A
9/30/2017	215	28	N/A	64	N/A
6/30/2017	193	35	N/A	73	N/A
3/31/2017	178	36	N/A	74	N/A
12/31/2016	165	28	N/A	67	N/A
9/30/2016	160	18	N/A	5	N/A
6/30/2016	148	6	N/A	-6	N/A
3/31/2016	144	17	N/A	-2	N/A
12/31/2015	128	17	N/A	16	N/A
9/30/2015	119	12	N/A	19	N/A
6/30/2015	104	11	N/A	23	N/A
3/31/2015	93	-4	N/A	9	N/A
12/31/2014	89	-7	N/A	-4	N/A
9/30/2014	85	-29	N/A	6	N/A
6/30/2014	89	-25	N/A	2	N/A
3/31/2014	86	-27	N/A	1	N/A
12/31/2013	86	-25	N/A	7	N/A
9/30/2013	83	-10	N/A	8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EVTは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 0.7% ) よりも高い成長率であると考えられます。

収益対市場: EVT今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EVT今後 3 年以内に収益を上げることが予想されます。

収益対市場: EVTの収益 ( 13.1% ) German市場 ( 5.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: EVTの収益 ( 13.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EVTの自己資本利益率は、3年後には低くなると予測されています ( 4.3 %)。

Evotec 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Price target decreased by 11% to €13.64

Consensus EPS estimates fall by 69%

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Consensus EPS estimates fall by 77%

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

Price target decreased by 7.0% to €19.26

Recent updates

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Price target decreased by 11% to €13.64

Consensus EPS estimates fall by 69%

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 77%

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Price target decreased by 7.0% to €19.26

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Price target decreased by 7.5% to €23.00

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Evotec SE, Annual General Meeting, Jun 20, 2023

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

Price target decreased by 8.1% to €24.93

Price target decreased by 9.8% to €24.73

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Consensus forecasts updated

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Consensus forecasts updated

Consensus EPS estimates have been upgraded.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Consensus forecasts updated

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Now 22% undervalued after recent price drop

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Now 22% undervalued after recent price drop

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Investor sentiment improved over the past week

Is Now The Time To Look At Buying Evotec SE (ETR:EVT)?

Evotec SE Confirms Revenue Guidance for 2022

Is Evotec (ETR:EVT) A Risky Investment?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Consensus forecasts updated